IMGN News and Press, ImmunoGen Inc. From 12/10/23

Pivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed Across All Molecular Subsets Evaluated Pivekimab-Containing Triplet Well-Tolerated with Manageable Safety Profile Data Support Continued Development of Trip...

2023-12-07 07:45:28 ET Summary Akoya Biosciences has seen a significant decline in its stock price but has recently bounced back by 55%. The company has shown consistent revenue growth over the past four years, with a projected revenue of up to $98.0 million for 2023. Akoya ha...

2023-12-07 06:05:00 ET Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. That's because it will need to become less reliant on Humira, its blockbuster rheumatoid arthritis drug, which is losing patent protection. ...

2023-12-07 05:36:06 ET Sanofi ( NASDAQ: SNY ) said on Thursday its multiple myeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial. The drug is currently indicated for use in a combination therapy for previously-treated relapsed or refractory mult...

2023-12-07 02:28:36 ET Summary Tech titans like Microsoft, Meta Platforms, Alphabet, and Amazon have experienced slight declines in their stock prices. I suggest waiting for a larger drop before buying these stocks isn't feasible, but highlight the potential for future growth in r...

2023-12-05 06:55:07 ET More on ImmunoGen AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time Immunogen's AbbVie Deal: Key Insights For Investors And Traders AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology Barclays cuts ImmunoGen ...

Priority Review Granted with PDUFA Date of April 5, 2024 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed the supplemental Biologic...

2023-12-04 16:18:03 ET More on ImmunoGen AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time Immunogen's AbbVie Deal: Key Insights For Investors And Traders AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology Biotechs post record gai...

2023-12-03 17:00:00 ET Summary AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading price. The acquisition provides AbbVie with a commercial-stage company and a flagship drug that generated $105 million in sales in Q3. Let's look at this m...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...